Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Heart ; 108(4): 258-265, 2022 02.
Article in English | MEDLINE | ID: covidwho-2137872

ABSTRACT

Ramadan fasting is observed by most of the 1.8 billion Muslims around the world. It lasts for 1 month per the lunar calendar year and is the abstention from any food and drink from dawn to sunset. While recommendations on 'safe' fasting exist for patients with some chronic conditions, such as diabetes mellitus, guidance for patients with cardiovascular disease is lacking. We reviewed the literature to help healthcare professionals educate, discuss and manage patients with cardiovascular conditions, who are considering fasting. Studies on the safety of Ramadan fasting in patients with cardiac disease are sparse, observational, of small sample size and have short follow-up. Using expert consensus and a recognised framework, we risk stratified patients into 'low or moderate risk', for example, stable angina or non-severe heart failure; 'high risk', for example, poorly controlled arrhythmias or recent myocardial infarction; and 'very high risk', for example, advanced heart failure. The 'low-moderate risk' group may fast, provided their medications and clinical conditions allow. The 'high' or 'very high risk' groups should not fast and may consider safe alternatives such as non-consecutive fasts or fasting shorter days, for example, during winter. All patients who are fasting should be educated before Ramadan on their risk and management (including the risk of dehydration, fluid overload and terminating the fast if they become unwell) and reviewed after Ramadan to reassess their risk status and condition. Further studies to clarify the benefits and risks of fasting on the cardiovascular system in patients with different cardiovascular conditions should help refine these recommendations.


Subject(s)
Cardiovascular Diseases , Heart Failure , Cardiovascular Diseases/therapy , Fasting/adverse effects , Heart Failure/therapy , Humans , Islam
2.
Diabetes Res Clin Pract ; 186: 109812, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1739664

ABSTRACT

OBJECTIVE: Muslim people with T1DM should be actively discouraged from fasting during the COVID-19 pandemic, as diabetes has emerged as a significant risk factor for adverse outcomes of COVID-19 infection. We report the experience of young patients with type 1, type 2 and other types diabetes who fasted during Ramadan 2020 at the time of the COVID-19 pandemic time lockdown. RESEARCH DESIGN AND METHODS: A Post- Ramadan survey was designed for young patients who fasted during Ramadan in 2020 during COVID pandemic time. The study was conducted to compared the basal characteristics and other parameters in children and adolescents (<18 years), with young adults (≥18 years) with diabetes at Paediatric Diabetes Center in BIRDEM in Bangladesh. RESULTS: Among the study participants, a significantly higher number of participants were in older age group who fasted for more than 15 days (p = 0.045). A considerable proportion (30.7%) of patients developed mild hypoglycaemia, and only eight patients (2.6%) developed moderate to severe hypoglycemia. There was significant reduction of post Ramadan basal insulin dose in both groups (p = 0.001). Although increased bolus insulin dose requirements were observed in older age group, but decreased requirement was observed in younger age group during Ramadan (p = 0.001). Post Ramadan median HbA1C in both groups was increased with marked increase in older age group compared to younger age group though it did not reach the statistical significance. (p = 0.239) CONCLUSIONS: COVID-19 pandemic had minor impact on fasting during Ramadan in our cohort, they could fast safely with less complications during Ramadan. Our data supports Ramadan focused diabetes education with ample self-care, young people with diabetes can fast safely during Ramadan.


Subject(s)
COVID-19 , Diabetes Mellitus, Type 1 , Hypoglycemia , Adolescent , Aged , Bangladesh/epidemiology , COVID-19/epidemiology , Child , Communicable Disease Control , Diabetes Mellitus, Type 1/epidemiology , Fasting/adverse effects , Glycated Hemoglobin/analysis , Humans , Hypoglycemia/epidemiology , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Islam , Pandemics , Young Adult
4.
PLoS One ; 17(1): e0262530, 2022.
Article in English | MEDLINE | ID: covidwho-1627791

ABSTRACT

BACKGROUND: The effect of fasting on immunity is unclear. Prolonged fasting is thought to increase the risk of infection due to dehydration. This study describes antibiotic prescribing patterns before, during, and after Ramadan in a primary care setting within the Pakistani and Bangladeshi populations in the UK, most of whom are Muslims, compared to those who do not observe Ramadan. METHOD: Retrospective controlled interrupted time series analysis of electronic health record data from primary care practices. The study consists of two groups: Pakistanis/Bangladeshis and white populations. For each group, we constructed a series of aggregated, daily prescription data from 2007 to 2017 for the 30 days preceding, during, and after Ramadan, respectively. FINDINGS: Controlling for the rate in the white population, there was no evidence of increased antibiotic prescription in the Pakistani/Bangladeshi population during Ramadan, as compared to before Ramadan (IRR: 0.994; 95% CI: 0.988-1.001, p = 0.082) or after Ramadan (IRR: 1.006; 95% CI: 0.999-1.013, p = 0.082). INTERPRETATION: In this large, population-based study, we did not find any evidence to suggest that fasting was associated with an increased susceptibility to infection.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Disease Susceptibility/metabolism , Fasting/adverse effects , Adult , Aged , Arabs , Communicable Disease Control/methods , Communicable Diseases/drug therapy , Communicable Diseases/transmission , Electronic Health Records , Female , Humans , Interrupted Time Series Analysis/methods , Islam , Male , Middle Aged , Practice Patterns, Physicians' , Primary Health Care/trends , Retrospective Studies , United Kingdom/epidemiology , White People
7.
Diabet Med ; 37(7): 1094-1102, 2020 07.
Article in English | MEDLINE | ID: covidwho-116685

ABSTRACT

The month of Ramadan forms one of the five pillars of the Muslim faith. Adult Muslims are obligated to keep daily fasts from dawn to sunset, with exceptions. This year Ramadan is due to begin on 23 April 2020 and the longest fast in the UK will be approximately 18 hours in length. In addition, due to the often high-calorie meals eaten to break the fast, Ramadan should be seen as a cycle of fasting and feasting. Ramadan fasting can impact those with diabetes, increasing the risk of hypoglycaemia, hyperglycaemia and dehydration. This year, Ramadan will occur during the global COVID-19 pandemic. Reports show that diabetes appears to be a risk factor for more severe disease with COVID-19. In addition, the UK experience has shown diabetes and COVID-19 is associated with dehydration, starvation ketosis, diabetic ketoacidosis and hyperosmolar hyperglycaemic state. This makes fasting in Ramadan particularly challenging for those Muslims with diabetes. Here, we discuss the implications of fasting in Ramadan during the COVID-19 pandemic and make recommendations for those with diabetes who wish to fast.


Subject(s)
Diabetes Mellitus, Type 1/therapy , Diabetes Mellitus, Type 2/therapy , Fasting/metabolism , Holidays , Islam , Betacoronavirus , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/metabolism , Dehydration/epidemiology , Dehydration/metabolism , Dehydration/prevention & control , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/metabolism , Diabetic Ketoacidosis/epidemiology , Diet Therapy , Disease Management , Fasting/adverse effects , Fluid Therapy , Humans , Hyperglycemia/epidemiology , Hyperglycemia/metabolism , Hyperglycemia/prevention & control , Hyperglycemic Hyperosmolar Nonketotic Coma/epidemiology , Hyperglycemic Hyperosmolar Nonketotic Coma/metabolism , Hypoglycemia/epidemiology , Hypoglycemia/metabolism , Hypoglycemia/prevention & control , Hypoglycemic Agents/therapeutic use , Ketosis/epidemiology , Ketosis/metabolism , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/metabolism , Risk Assessment , SARS-CoV-2 , United Kingdom
SELECTION OF CITATIONS
SEARCH DETAIL